Pemphigus foliaceus (PF) is diagnosed by histopathology confirming subcorneal pustular dermatitis with acantholytic keratinocytes, and managed with long-term systemic immunosuppression — typically glucocorticoids as the foundation, with adjunctive agents added for refractory or severe disease.
Diagnosis begins with cytology and is confirmed by biopsy. Cytology of intact pustules reveals rounded acantholytic epithelial cells with nuclei and basophilic cytoplasm, along with neutrophils and rarely eosinophils.Journal of the… Histopathology is the gold standard, demonstrating subcorneal pustules containing rafts of or individualized acantholytic cells.Journal of the… The biopsy site should not be scrubbed prior to sampling — clipping the hair is permissible, but scrubbing disrupts the diagnostic lesion.Journal of the… Direct immunofluorescence detects tissue-bound autoantibodies and supports the diagnosis; indirect immunohistochemistry demonstrating IgG-positive staining around keratinocytes is an alternative.Journal of the… In dogs with concurrent immune-mediated thrombocytopenia (IMT), platelet surface-associated immunoglobulin detected by flow cytometry confirms the hematologic comorbidity.Journal of the…
Lesion distribution guides clinical suspicion. Canine PF classically affects the trunk, ears, and face, with pustules that rapidly progress to crusts and erosions.Journal of the… Footpad-dominant and mucocutaneous junction involvement occurs but is less common.Journal of the… Lesions on constantly traumatized surfaces such as footpads are dominated by crusting rather than intact pustules due to easy rupture from friction.Journal of the… Bilateral symmetry is characteristic.Veterinary Derm… Systemic signs including fever are possible, particularly when concurrent vasculitis or hematologic autoimmune disease is present.Veterinary Derm…+1
First-line treatment is systemic glucocorticoids at immunosuppressive doses. Prednisone or prednisolone is the recommended initial therapy.Brazilian Journ… Dogs with concurrent overt vasculitis take a median of 93.8 days to achieve remission, compared with 41.8 days in dogs without vasculopathic lesions, and are more likely to experience treatment-associated adverse effects.Veterinary Derm… Dogs with concurrent vasculopathy or vasculitis are also more likely to present with systemic signs of illness.Veterinary Derm…
Oclacitinib (Apoquel; Zoetis) is an effective adjunctive or alternative agent for glucocorticoid-refractory PF. When combined with glucocorticoids, oclacitinib achieved some degree of remission (partial or complete) in 11 of 15 dogs, with an average glucocorticoid dose reduction of 64.4%; 3 of 15 dogs achieved complete glucocorticoid elimination.Veterinary Derm… Azathioprine combined with glucocorticoids achieved remission in 13 of 15 dogs, with an average glucocorticoid dose reduction of 77.9%; 1 of 15 dogs achieved complete glucocorticoid elimination.Veterinary Derm… There was no statistically significant difference in remission rates or glucocorticoid-sparing effect between the two adjunctive agents.Veterinary Derm… Oclacitinib has also been used as monotherapy in a dog unresponsive to oral corticosteroids, with documented efficacy.Brazilian Journ…
Cyclosporine at 5–6 mg/kg/day combined with prednisolone is an established regimen for complex or comorbid cases. This combination achieved remission in dogs with concurrent PF and generalized discoid lupus erythematosus, using either high-dose pulse or standard immunosuppressive prednisolone protocols.Veterinary Derm… Cyclosporine combined with azathioprine was effective in a dog with concurrent PF and IMT, with survival exceeding 2 years from initial presentation.Journal of the…
Bruton's tyrosine kinase inhibitor PRN1008 is an emerging option for refractory disease. At final daily doses of 17–33 mg/kg, 3 of 4 dogs achieved near-complete remission by 20 weeks, with responses rated "good" in 3 dogs and "fair" in 1 dog.Veterinary Derm… One possible adverse event was recorded.Veterinary Derm…
Therapeutic plasma exchange (TPE) is a rescue option for severe, generalized, refractory PF. Four TPE treatments produced a 50% reduction in lesional body surface area in a dog with severe refractory disease.Veterinary Derm…
Treatment is long-term to lifelong in most dogs. Management relies on sustained immunosuppressive therapy, and the goal is the lowest effective dose of each agent to minimize adverse effects.Veterinary Clin…
| Agent | Dose / Protocol | Efficacy in PF | Key Caveat |
|---|---|---|---|
| Prednisone / Prednisolone | Immunosuppressive doses (exact mg/kg not specified in sources) | First-line; standard of care | Vasculitis prolongs remission to 93.8 days vs. 41.8 days Veterinary Derm… |
| Oclacitinib + glucocorticoid | Not specified in sources | Remission in 11/15 dogs; 64.4% GC dose reduction; 3/15 complete GC elimination Veterinary Derm… | No significant difference vs. azathioprine Veterinary Derm… |
| Azathioprine + glucocorticoid | Not specified in sources | Remission in 13/15 dogs; 77.9% GC dose reduction; 1/15 complete GC elimination Veterinary Derm… | No significant difference vs. oclacitinib Veterinary Derm… |
| Cyclosporine + prednisolone | 5–6 mg/kg/day cyclosporine Veterinary Derm… | Remission achieved in comorbid PF + GDLE cases Veterinary Derm… | Also effective with azathioprine in PF + IMT Journal of the… |
| BTK inhibitor PRN1008 | 17–33 mg/kg/day (final doses) Veterinary Derm… | Near-complete remission in 3/4 dogs by 20 weeks Veterinary Derm… | One possible adverse event; emerging therapy Veterinary Derm… |
| Therapeutic plasma exchange | 4 treatments Veterinary Derm… | 50% reduction in lesional BSA Veterinary Derm… | Reserved for severe, refractory, generalized disease Veterinary Derm… |
Would you like guidance on how to taper glucocorticoids once remission is achieved in canine PF?